Marinus Pharmaceuticals Announced That Additional Data From Phase 3 RAISE Trial In Refractory Status Epilepticus And Retrospective Claims-based Data From Patients With Status Epilepticus Will Be Presented At The Upcoming Neurocritical Care Society Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals will present additional data from its Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data at the Neurocritical Care Society Annual Meeting.
October 09, 2024 | 11:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharmaceuticals is set to present new data from its Phase 3 RAISE trial, which could impact perceptions of its drug development progress in refractory status epilepticus.
The presentation of new data from a Phase 3 trial is significant for Marinus Pharmaceuticals as it could influence investor sentiment and stock price. Positive data could lead to increased investor confidence in the company's drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90